alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 10.623

[CHIRON
LETTERHEAD]

CONFIDENTIAL

Dear
John,

As
you are aware, we are in the process of reorganizing our business in the United Kingdom, with the result that Chiron Corporation Limited will be transferring part of its U.K. business
to an Italian company, Chiron Vaccines Holding s.r.l. (the "Company").

New Employer

The practical consequence of this reorganization is that from 1 July 2003 you will be employed by Chiron Vaccines
Holding s.r.l.UK Branch. However, with the exception of the name and identity of your employer, your existing terms and conditions of employment will otherwise be
unaffected, and your period of continuous employment with Chiron Corporation Limited will be preserved for employment law purposes.

The
principal effect to your personal affairs arising from this transfer is that you will become subject to taxation on your income under both the Italian tax regime and that of the U.K.

Tax Equalization

Chiron intends to apply the following policy in respect of this transfer regarding your tax liabilities during your employment:







---



Reimbursement and Indemnity

In accordance with the tax equalisation policy outlined above, we would like to assure you that Chiron Vaccines Holding s.r.l. will:



The
obligation to reimburse and indemnify contained above is given by the companies below for and on behalf themselves and any successor or assignee group company to which either of them
or their respective business and assets may at any time succeed or be assigned.

If
you have any questions in relation to this variation to your contract of employment, please contact Katrien Nachtergaele. To acknowledge your agreement to the change of employer
outlined above, please sign and date the attached duplicate of this letter and return to Katrien.

Yours
sincerely,

/s/JOHN A. LAMBERT

John
A. Lambert
For and on behalf of Chiron Corporation Limited

Giuseppe
M. Marini
For and on behalf of Chiron Vaccines Holding s.r.l.

|                   |  | 
|------------------ |  | 
|/s/GIUSEPPE MARINI |  | 

I
confirm that I have read the above letter and agree to the variation of my contract of employment as stated.

|                |  |                    |  |        |  |               
|--------------- |  | ------------------ |  | ------ |  | --------------
|Signed:         |  | /s/JOHN A. LAMBERT |  | Dated: |  | 1st July 2003.
|John A. Lambert |  |                    |  |       

---

QuickLinks
HomeOffice of the SpokespersonPress Releases...Finland’s Accession to NATO

# 									Finland’s Accession to NATO							

Press Statement

Antony J. Blinken, Secretary of State

April 4, 2023

On this historic day as we mark the 74th anniversary of NATO, we also welcome Finland as NATO’s 31st Ally.  Finland is stronger and safer within the Alliance, and the Alliance is stronger and safer with Finland as its Ally.  Finland has a highly capable military and has been an active participant in NATO-led operations; it also shares our values and strong democratic institutions.  We are confident Finland’s membership will strengthen our collective defense and enhance our ability to respond to security challenges in the Euro-Atlantic area.

Russia’s further invasion into Ukraine last year precipitated the very thing President Putin wanted to avoid: a stronger, more unified, Transatlantic Alliance.  Sweden is also a strong and capable partner that is ready to join NATO.  We encourage Türkiye and Hungary to ratify the accession protocols for Sweden without delay so we can welcome Sweden into the Alliance as soon as possible.

NATO has helped maintain peace and stability in Europe for over 70 years.  It has also played a critical role in promoting stability and the international rules-based order around the world.  Finland’s membership in the Alliance will advance these shared goals.

Tags

Bureau of European and Eurasian AffairsDefenseDemocracyFinlandNorth Atlantic Treaty OrganizationOffice of the SpokespersonSecretary TripThe Secretary of StateSecurity

Back to Top
EXHIBIT
21





CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





In
connection with the Annual Report of Utah Medical Products, Inc. (the “Company”)
on Form 10-K for the fiscal year ending December 31, 2007, as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), I, Kevin
L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that, to the best of my knowledge and belief:





(1)
              the
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and





(2)
              the
      information contained in the Report fairly presents, in all material
      respects, the financial condition and result of operations of the
      Company.











/s/ Kevin L.
Cornwell


Kevin L.
Cornwell


Chief
Executive Officer


March 6,
2008





A
signed original of this written statement required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement
has been provided to the Company and will be retained by the Company and
furnished to the Securities and Exchange Commission or its staff upon
request.
<PAGE>

                                                                    EXHIBIT 32.1

                             CERTIFICATE PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Mason N. Carter, Chief Executive Officer of Merrimac
Industries, Inc. (the "Company"), hereby certifies, pursuant to 18 U.S.C. 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

     (1) The Company's Annual Report on Form 10-KSB for the fiscal year ending
     January 3, 2004, as filed with the Securities and Exchange Commission on
     the date hereof (the "Annual Report"), fully complies with the requirements
     of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

     (2) The information contained in the Annual Report fairly presents, in all
     material respects, the financial condition and results of operations of the
     Company.




/s/ Mason N. Carter
-------------------
Mason N. Carter
Chief Executive Officer
March 31, 2004
# C_2006034EN.01002901.xml

| 10.2.2006 | EN | Official Journal of the European Union | C 34/29 |
| --- | --- | --- | --- |

10.2.2006

EN

Official Journal of the European Union

C 34/29

---

Appointment of the Registrar

(2006/C 34/07)

The term of office of Mr Roger Grass, Registrar of the Court of Justice of the European Communities, expired on 9 February 2006.

The Court of Justice, at its General Meeting on 28 June 2005, decided to renew the term of office of Mr Roger Grass in accordance with Article 12 of the Rules of Procedure for the period from 10 February 2006 to 9 February 2012 inclusive.

---
Editorial Note on Part 414
Editorial Note: Nomenclature changes to part 414 appear at 60 FR 50442, Sept. 29, 1995, and 60 FR 53877, Oct. 18, 1995.

§ 414.232 Special payment rules for transcutaneous electrical nerve stimulators (TENS). ( a ) *General payment rule.* Except as provided in paragraph (b) of this section, payment for TENS is made on a purchase basis with the purchase price determined using the methodology for purchase of inexpensive or routinely purchased items as described in § 414.220. The payment amount for TENS computed under § 414.220(c)(2) is reduced according to the following formula: ( 1 ) Effective April 1, 1990—the original payment amount is reduced by 15 percent.
( 2 ) Effective January 1, 1991—the reduced payment amount in paragraph (a)(1) is reduced by 15 percent.
( 3 ) Effective January 1, 1994—the reduced payment amount in paragraph (a)(1) is reduced by 45 percent.
( b ) *Exception.* In order to permit an attending physician time to determine whether the purchase of the TENS is medically appropriate for a particular patient, two months of rental payments may be made in addition to the purchase price. The rental payments are equal to 10 percent of the purchase price.
[57 FR 57692, Dec. 7, 1992, as amended at 60 FR 35498, July 10, 1995]
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT
No. 95-2093
WILLIAM TRACY OWENS, Plaintiff - Appellant, versus WARREN MASSENBURG, Defendant - Appellee.
Appeal from the United States District Court for the Eastern District of North Carolina, at Raleigh. W. Earl Britt, District Judge. (MISC-93-187-5) Submitted: January 18, 1996 Decided: February 15, 1996 Before HAMILTON and LUTTIG, Circuit Judges, and CHAPMAN, Senior Circuit Judge. Dismissed by unpublished per curiam opinion. William Tracy Owens, Appellant Pro Se. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM: Appellant noted this appeal outside the thirty-day appeal period established by Fed. R. App. P. 4(a)(1), failed to obtain an extension of the appeal period within the additional thirty-day period provided by Fed. R. App. P. 4(a)(5), and is not entitled to relief under Fed. R. App. P. 4(a)(6). The time periods established by Fed. R. App. P. 4 are "mandatory and jurisdictional." Browder v. Director, Dep't of Corrections , 434 U.S. 257, 264 (1978) (quoting United States v. Robinson , 361 U.S. 220, 229 (1960)). The district court entered its order on February 7, 1994; Appellant's notice of appeal was filed on May 5, 1995. Appellant's failure to note a timely appeal or obtain an extension of the appeal period deprives this court of jurisdiction to consider this case. We therefore denyleave to proceed in forma pauperis and dismiss the appeal. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

DISMISSED
# C_2006036EN.01002602.xml

| 11.2.2006 | EN | Official Journal of the European Union | C 36/26 |
| --- | --- | --- | --- |

11.2.2006

EN

Official Journal of the European Union

C 36/26

---

Action brought on 16 December 2005 by the Commission of the European Communities against the Italian Republic

(Case C-449/05)

(2006/C 36/53)

Language of the case: Italian

An action against the Italian Republic was brought before the Court of Justice of the European Communities on 16 December 2005 by the Commission of the European Communities, represented by C. Cattabriga and S. Visaggio, acting as Agents, with an address for service in Luxembourg.

The Commission claims that the Court should:

| 1. | declare that by not taking all the necessary legal and administrative measures to comply with Directive 2003/99/EC of the European Parliament and of the Council of 17 November 2003 (1) on the monitoring of zoonoses and zoonotic agents, amending Council Decision 90/424/EEC (2) and repealing Council Directive 92/117/EEC (3), or by not notifying the Commission of such measures, the Italian Republic has failed to fulfil its obligations under the first paragraph of Article 14(1) of that directive. |
| --- | --- |

1.

declare that by not taking all the necessary legal and administrative measures to comply with Directive 2003/99/EC of the European Parliament and of the Council of 17 November 2003 (1) on the monitoring of zoonoses and zoonotic agents, amending Council Decision 90/424/EEC (2) and repealing Council Directive 92/117/EEC (3), or by not notifying the Commission of such measures, the Italian Republic has failed to fulfil its obligations under the first paragraph of Article 14(1) of that directive.

1

2

3

| 2. | order the Italian Republic to pay the costs. |
| --- | --- |

2.

order the Italian Republic to pay the costs.

Pleas in law and main arguments

The period for implementing the directive expired on 12 April 2004.

---

(1)  OJ L 325, 12.12.2003, p. 31.

1

(2)  OJ L 224, 18.8.1990, p. 19.

2

(3)  OJ L 62, 15.3.1993, p. 38.

3

---
#### Freddie DELEON, Appellant, v. STATE of Florida, Appellee.

No. 81-265.

District Court of Appeal of Florida, Fifth District.

Dec. 2, 1981.

*1227James B. Gibson, Public Defender, and Christopher S. Quarles, Asst. Public Defender, Daytona Beach, for appellant.

Jim Smith, Atty. Gen., Tallahassee, and James Dickson Crock, Asst. Atty. Gen., Daytona Beach, for appellee.

SHARP, Judge.

AFFIRMED.

*See Pendarvis v. State,*400 So.2d 494 (Fla. 5th DCA 1981).

ORFINGER and COWART, JJ., concur.
# C_2006048EN.01003002.xml

| 25.2.2006 | EN | Official Journal of the European Union | C 48/30 |
| --- | --- | --- | --- |

25.2.2006

EN

Official Journal of the European Union

C 48/30

---

Judgment of the Court of First Instance of 14 December 2005 — Regione autonoma della Sardegna v Commission

(Case T-200/04) (1)

1

(State aid - Measures on the part of the Italian authorities aimed at compensating for the damage caused by ovine catarrhal fever (blue tongue) - Guidelines concerning State aid in the agricultural sector)

(2006/C 48/57)

Language of the case: Italian

Parties

Applicant: Regione autonoma della Sardegna (represented by: D. Dodaro and S. Cianciullo, lawyers)

Applicant:

Defendant: Commission of the European Communities (represented by: V. Di Bucci, Agent)

Defendant:

:

Application for

Annulment of Commission Decision C(2004) 471 Final of 16 March 2004 concerning the aid scheme which Italy is planning to implement in favour of processing and marketing cooperatives in order to compensate the damage caused by ovine catarrhal fever (blue tongue) (Article 5 of Law No 22 of the Region of Sardinia of 17 November 2000)

Operative part of the judgment

The Court:

| 1. | Dismisses the application; |
| --- | --- |

1.

Dismisses the application;

| 2. | Orders the applicant to pay the costs. |
| --- | --- |

2.

Orders the applicant to pay the costs.

---

(1)  OJ C 217, 28.8.2004.

1

---
#### STATE of Louisiana v. Arthur EDWARDS, Jr.

No. 80-K-2582.

Supreme Court of Louisiana.

Nov. 26, 1980.

In re Arthur Edwards, Jr., applying for writs of certiorari, prohibition, and mandamus. Parish of Caddo. No. 114961.

Granted in part and denied in part. Relator is to be paid cost of transcript out of funds available for transcripts for indigent defendants. Otherwise denied.

DIXON, C. J., CALOGERO and DENNIS, JJ., would grant the writ.
# C_2006143EN.01002901.xml

| 17.6.2006 | EN | Official Journal of the European Union | C 143/29 |
| --- | --- | --- | --- |

17.6.2006

EN

Official Journal of the European Union

C 143/29

---

Order of the President of the Court of 14 November 2005 — Commission of the European Communities v Hellenic Republic

(Case C-526/03) (1)

1

(2006/C 143/55)

Language of the case: Greek

Language of the case: Greek

The President of the Court has ordered that the case be removed from the register.

---

(1)  OJ C 71, 20.03.2004.

1

---
[Federal Register Volume 74, Number 172 (Tuesday, September 8, 2009)]
[Notices]
[Pages 46228-46229]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-21540]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in schedule I or II and prior to issuing a 
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of 
such a substance, provide manufacturers holding registrations for the 
bulk manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Title 21 Code of Federal Regulations 
(CFR), 1301.34(a), this is notice that on July 2, 2009, GE Healthcare, 
3350 North Ridge Avenue, Arlington Heights, Illinois 60004-1412, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as an importer of Cocaine (9041), a basic class of 
controlled substance listed in schedule II.
    The company plans to import small quantities of ioflupane, in the 
form of three separate analogues of Cocaine, to validate production and 
quality control systems, for a reference standard, and for producing 
material for a future investigational new drug (IND) submission.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic class of controlled 
substance may file comments or objections to the issuance of the 
proposed registration and may, at the same time, file a written request 
for a hearing on such application pursuant to 21 CFR 1301.43 and in 
such form as prescribed by 21 CFR 1316.47.
    Any such comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, VA. 22152; and must be filed no later 
than October 8, 2009.

[[Page 46229]]

    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, (40 FR 43745-46), all 
applicants for registration to import a basic class of any controlled 
substance in schedule I or II are and will continue to be, required to 
demonstrate to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, that the requirements for 
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: August 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-21540 Filed 9-4-09; 8:45 am]
BILLING CODE 4410-09-P
p. 1 

RECEIVED 

OPPT CE3IC Enst at 2OItoy 12 111111: 07 

Sincerely, 

DuPont Chemicals and Fluoroproducts 

Chambers Works 

Deepwater, NJ 08023 

October 31, 2014 

Director, Chemical Control Division 

US Environmental Protection Agency 

Office of Pollution Prevention and Toxics 

EPA East 

Room 4146 

1201 Constitution Avenue, NW 

Washington, DC 20004 

Re: EPA — HQ — OPPT — 2003 - 0012 

DuPont Chambers Works NJPDES Permit No. NJ0005100 

PFOA Data Submittal — Outfall DSN662 Weekly Grab Samples 

September 2014 Sample Data 

Dear Chemical Control Division: 

CBIC Control Number 

362575 

Attached please find summaries of PFOA analytical results for the DuPont Chambers Works 

weekly grab samplq taken at internal outfall DSN662A in September 2014.4In accordance with 

the current site NJPICES permit (NJ0005100, effective September 2011), the& results are 

provided to NJDEP on a monthly basis via electronic discharge monitoring reports. The 

enclosures include two paper and two electronic copies of the analytical results from this 

monitoring period. 

Amu a Jeyarajasingam 

Area Manager-Secure Environmental Treatment 

DuPont Chambers Works 

AJ/cic 

Enclosures 
Copy to: 

/

Document Control Office 

US Environmental Protection Agency 

Office of Pollution Prevention and Toxics 

EPA East 

Room 6428 

1200 Pennsylvania Avenue, NW 

Washington, DC 20460 

Ms. Susan Rosenwinkel (cover letter only) 

Principal Environmental Engineer 

NJDEP Division of Water Quality 

Bureau of Water Surfacing 

Mail Code 401-02B 

401 E. State Street 

P.O. Box 420 

Trenton, NJ 08625-0420 

p. 2 
P. 3 

ug/L =micrograms perLiter 

662-GRAB 

9/29/14 

0 0 .,— 

1969 

PFOA=PerfluorooctanoicAcid 

Sampleswereanalyzed byCritical Path Services LLC.Reborted results 

representasingleanalysis,except forthesamplecollected on9/1 /14. I 

Acceptableprecisionwasobtained and thereported result forthesamr collected on9/1 /14 representstheaverageof lab duplicateresults. 

1TheNJDEP labcertification numberfor Critical Path ServicesLLC isPAU; 

662-GRAB1 

1 171.2Z/6 

0 0 ,— 

1L• 9 1. 

ug/L =m icrog ramsperliterorpartsperbillion (ppb) 

662-GRABI 

li4/9 1.16 

0 0 1— 

I [5.9 

LOQ =lim itof quantification =0. 100ug/L 1 

662-GRAB1 

9/8/141 

0 0 ,— 

1 L99 

662-GRAB1 

1 1714146 

0 0 1— 

L8 17 

' SampleIDI 

I owa 

Top(ft)I 

Bottom(ft)I 

Duplicate #1 

0 

I— 

I(a) •ssia ri

I— 

m-7F 

1/6n 

. auc ie uvl 

LI0- 

<and ND =Nondetectatstated reportinglimit
# C_2006027EN.01000201.xml

| 3.2.2006 | EN | Official Journal of the European Union | C 27/2 |
| --- | --- | --- | --- |

3.2.2006

EN

Official Journal of the European Union

C 27/2

---

Euro exchange rates (1)

1

2 February 2006

(2006/C 27/02)

1 euro=

1 euro

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,2066 |
| JPY | Japanese yen | 143,04 |
| DKK | Danish krone | 7,4654 |
| GBP | Pound sterling | 0,67880 |
| SEK | Swedish krona | 9,2835 |
| CHF | Swiss franc | 1,5555 |
| ISK | Iceland króna | 76,34 |
| NOK | Norwegian krone | 8,0505 |
| BGN | Bulgarian lev | 1,9558 |
| CYP | Cyprus pound | 0,5739 |
| CZK | Czech koruna | 28,513 |
| EEK | Estonian kroon | 15,6466 |
| HUF | Hungarian forint | 250,78 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,6960 |
| MTL | Maltese lira | 0,4293 |
| PLN | Polish zloty | 3,8175 |
| RON | Romanian leu | 3,6055 |
| SIT | Slovenian tolar | 239,47 |
| SKK | Slovak koruna | 37,371 |
| TRY | Turkish lira | 1,6030 |
| AUD | Australian dollar | 1,6029 |
| CAD | Canadian dollar | 1,3786 |
| HKD | Hong Kong dollar | 9,3604 |
| NZD | New Zealand dollar | 1,7557 |
| SGD | Singapore dollar | 1,9708 |
| KRW | South Korean won | 1 173,30 |
| ZAR | South African rand | 7,3826 |
| CNY | Chinese yuan renminbi | 9,7262 |
| HRK | Croatian kuna | 7,3300 |
| IDR | Indonesian rupiah | 11 281,71 |
| MYR | Malaysian ringgit | 4,523 |
| PHP | Philippine peso | 62,852 |
| RUB | Russian rouble | 34,0080 |
| THB | Thai baht | 47,480 |

Currency

Exchange rate

USD

US dollar

1,2066

JPY

Japanese yen

143,04

DKK

Danish krone

7,4654

GBP

Pound sterling

0,67880

SEK

Swedish krona

9,2835

CHF

Swiss franc

1,5555

ISK

Iceland króna

76,34

NOK

Norwegian krone

8,0505

BGN

Bulgarian lev

1,9558

CYP

Cyprus pound

0,5739

CZK

Czech koruna

28,513

EEK

Estonian kroon

15,6466

HUF

Hungarian forint

250,78

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,6960

MTL

Maltese lira

0,4293

PLN

Polish zloty

3,8175

RON

Romanian leu

3,6055

SIT

Slovenian tolar

239,47

SKK

Slovak koruna

37,371

TRY

Turkish lira

1,6030

AUD

Australian dollar

1,6029

CAD

Canadian dollar

1,3786

HKD

Hong Kong dollar

9,3604

NZD

New Zealand dollar

1,7557

SGD

Singapore dollar

1,9708

KRW

South Korean won

1 173,30

ZAR

South African rand

7,3826

CNY

Chinese yuan renminbi

9,7262

HRK

Croatian kuna

7,3300

IDR

Indonesian rupiah

11 281,71

MYR

Malaysian ringgit

4,523

PHP

Philippine peso

62,852

RUB

Russian rouble

34,0080

THB

Thai baht

47,480

---

(1)

1

Source: reference exchange rate published by the ECB.

Source:

---